PHAT
Phathom Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.08
−10.56%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$5.70
From 52W high−71.90%
Volume1.54M
Market cap$412.96M
P/E (TTM)—
P/S (TTM)1.5x
Div yield—
Key dataNov 5, 2026
Open
$5.70
From 52W high
−71.90%
Volume
1.54M
Market cap
$412.96M
ValuationView details →
P/E (Fwd)
23.5x
EV/EBITDA
−20.0x
P/E (TTM)
—
RSI (14)
30.8
MomentumView details →
1D Return
−10.56%
YTD Return
−67.87%
SummaryUpdated Sep 1, 2026
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Florham Park, New Jersey. The company went public in October 2019 and focuses on developing and commercializing novel treatments for gastrointestinal diseases. Phathom's primary asset is <b>VOQUEZNA</b> (vonoprazan), a potassium-competitive acid blocker that represents a new class of acid-suppressing medications for treating stomach acid-related conditions. The company has successfully launched VOQUEZNA in the United States and is working to expand its commercial footprint while developing additional indications for the drug.
Similar companies
Latest newsMore news →
Phathom Pharmaceuticals, Inc. announced that eligible commercially insured patients may now pay as little as $0 for VOQUEZNA tablets exclusively through BlinkRx.2d agoPhathom Pharmaceuticals reported quarterly earnings of $0.04 per share, compared with a loss of $0.15 per share a year earlier.7d agoPhathom Pharmaceuticals, Inc. reported third-quarter 2026 net revenues of $84.7 million, up 71% year over year.7d ago